ampalex
Small moleculeexperimental
CX-516 is an ampakine and nootropic that acts as an AMPA receptor positive allosteric modulator and had been undergoing development by a collaboration between Cortex, Shire, and Servier. It was studied as a potential treatment for Alzheimer's disease under the brand name Ampalex, and was also being examined as a treatment for ADHD. — Wikipedia
Clinical trial activity
2 trials · 2 clinical orgs · 0 marketing orgs
Phase 1
0
Phase 2
2
Phase 3
0
Phase 4
0
Earliest trial started Apr 1, 2002 (NCT00040443)
Timeline
2000s
- Jan 1, 2002
Earliest Phase 2 Sponsor(trial)
Indications
Mechanism of action
- Glutamate receptor AMPA 1/2MODULATOR
Glutamate receptor AMPA 1/2 modulator
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Sources
- WikipediaCX-516 ↗
Also known as
- ampalex
- ampalex
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT00054730 | Phase 2 | Jun 1, 2002 | FRAXA Research Foundation, RespireRx |
| NCT00040443 | Phase 2 | Apr 1, 2002 | RespireRx |
Showing 2 of 2 trials
Page 1 / 1
Organizations
Research & Development (2)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| RespireRx | For profit | 2 | 2 | 1 | 2002 |
| FRAXA Research Foundation | Academic/Hospital | 1 | 0 | 1 | 2002 |
2 organizations
Page 1 / 1